微型RNA市场规模、份额、成长分析（按产品/服务、按应用、按最终用途、按地区）- 行业预测，2024-2031 年

2022年全球微型RNA市场规模将为12亿美元，从2023年的13.5亿美元成长到2031年的35.8亿美元，预测期（2024-2031）预计复合年增长率为12.90%。

近年来，在分子生物学、基因组学和生物资讯学进步的推动下，全球微型RNA市场出现了显着成长。 微型RNA(miRNA) 是调节基因表现所必需的小非编码 RNA 分子，已被定位为各种疾病的有价值的生物标记和新治疗方法的潜在目标。 miRNA 在诊断和治疗方面的潜力，以及对其在疾病过程中作用的更好理解，是市场扩张的主要驱动力。癌症、心血管疾病和神经系统疾病等慢性疾病的增加导致了该领域研究和投资的增加，因为 miRNA 在疾病诊断、预后和治疗方面具有广阔的前景，进一步推动了这一增长。此外，次世代定序和微阵列平台等技术进步正在增强 miRNA 分析和检测，支持市场开拓。然而，市场面临一些挑战。基于 miRNA 的治疗和诊断的复杂监管环境是一个主要障碍，需要严格的要求和昂贵的临床试验。确保基于 miRNA 的产品的安全性、有效性和特异性至关重要，但也充满挑战。由于对 miRNA 功能和生物系统内相互作用的了解有限，研究也变得复杂。由于需要标靶递送和稳定性，开发 miRNA 疗法的有效递送系统也是一个挑战。儘管存在这些障碍，全球微型RNA市场仍存在巨大的成长和创新机会，技术进步、研究的增加以及有助于开发新的基于 miRNA 的诊断和治疗方法的合作预计将得到促进。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 市场生态系统
• 供应链分析
• 案例研究分析
• PESTLE分析
• 监管环境
• 创新矩阵
• 重点投资分析
• 关键成功因素
• 竞争程度

微型RNA市场：依产品/服务分类

• 市场概况
• 服务
  • 类型
  • 分离/精製
  • miRNA cDNA 合成
  • 分析、本地化和量化
  • 泛函分析
  • 其他的
  • 检体
  • 全血
  • 血清
  • 电浆
  • FFPE
  • 新鲜冷冻组织
  • 其他的
• 产品
  • 装置
  • 科技
  • 即时PCR
  • 微阵列
  • 下一代种子
  • 其他的
  • 工作流程
  • 分离/精製
  • miRNA cDNA 合成
  • 分析、本地化和量化
  • 泛函分析等
  • 其他的
  • 消耗品
  • 检体
  • 工作流程
  • 分离/精製
  • miRNA cDNA 合成
  • 分析、本地化和量化
  • 泛函分析等
  • 其他的
  • 全血
  • 血清
  • 电浆
  • FFPE
  • 新鲜冷冻组织
  • 其他的

微型RNA市场：依应用分类

• 市场概况
• 癌症
• 感染疾病
• 免疫疾病
• 心血管疾病
• 神经系统疾病
• 其他的

微型RNA市场：依最终用途分类

• 市场概况
• 生技/製药公司
• 学术机构/政府研究机构
• 其他的

微型RNA市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Thermo Fisher Scientific, Inc.（US）
• QIAGEN（Germany）
• NanoString Technologies, Inc.（US）
• Merck KGaA（Germany）
• Takara Bio, Inc.（Japan）
• BioGenex（US）
• GeneCopoeia, Inc.（US）
• New England Biolabs（US）
• Agilent Technologies, Inc.（US）
• Illumina, Inc.（US）
• Abcam plc（UK）
• Roche Holding AG（Switzerland）
• Arcturus Therapeutics Ltd.（US）
• Synthego Corporation（US）
• Bio-Techne Corporation（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Asuragen, Inc.（US）
• Cell Signaling Technology, Inc.（US）
• Molecular Cloud（China）
• Ribomed Biotechnologies, Inc.（US）
• Sirnaomics Inc.（US）

Global MicroRNA Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3.58 billion by 2031, growing at a CAGR of 12.90% during the forecast period (2024-2031).

The global microRNA market has experienced notable growth recently, fueled by advances in molecular biology, genomics, and bioinformatics. MicroRNAs (miRNAs) are small non-coding RNA molecules essential for regulating gene expression, positioning them as valuable biomarkers for various diseases and potential targets for new therapies. Increased understanding of miRNA's role in disease processes, alongside its potential in diagnostics and treatments, has significantly driven market expansion. The rise in chronic diseases, such as cancer, cardiovascular conditions, and neurological disorders, further supports this growth, as miRNAs show promise in disease diagnosis, prognosis, and treatment, leading to more research and investment in the field. Additionally, advancements in technologies like next-generation sequencing and microarray platforms have enhanced miRNA profiling and detection, boosting market development. However, the market faces several challenges. Navigating the complex regulatory landscape for miRNA-based therapeutics and diagnostics is a major hurdle, with stringent requirements and costly clinical trials. Ensuring the safety, efficacy, and specificity of miRNA-based products is critical but challenging. Limited understanding of miRNA functions and their interactions within biological systems also complicates research. Developing effective delivery systems for miRNA therapeutics is another challenge due to the need for targeted delivery and stability. Despite these obstacles, the global microRNA market holds substantial opportunities for growth and innovation, with technological advancements, increased research, and collaborative efforts expected to drive the development of new miRNA-based diagnostics and treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MicroRNA market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global MicroRNA Market Segmental Analysis

Global MicroRNA Market is segmented by Products & Services, Application, End-use, and region. Based on Products & Services, the market is segmented into services, and products. Based on Application, the market is segmented into Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, and Others. Based on End-use, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global MicroRNA Market

Recent technological strides in genomics and molecular biology, particularly through next-generation sequencing and microarray platforms, have revolutionized the analysis of microRNAs. These advanced tools facilitate high-throughput examination, allowing researchers to identify and characterize microRNAs with greater efficiency. As a result, the capabilities of these technologies have spurred a surge in research activities, significantly contributing to the expansion of the microRNA market. The enhanced ability to analyze microRNAs has opened new avenues for discovery and innovation, further propelling market growth.

Restraints in the Global MicroRNA Market

Despite extensive research on microRNAs, their exact functions and mechanisms remain incompletely understood. This gap in knowledge presents challenges in pinpointing reliable and specific biomarkers, as well as in creating effective therapeutic strategies. The ongoing uncertainty surrounding microRNA biology complicates efforts to develop precise diagnostic and treatment options. Addressing these gaps is crucial for advancing the field and fully leveraging the potential of microRNAs in clinical applications.

Market Trends of the Global MicroRNA Market

Partnerships among biotechnology and pharmaceutical companies, academic research institutions, and government agencies are becoming more prevalent in the field of microRNA research. These collaborations combine the expertise, resources, and insights of various stakeholders, aiming to expedite the development and market introduction of microRNA-based products and solutions. By pooling their strengths, these collaborative efforts enhance the efficiency of research and development processes, driving innovation and accelerating the advancement of microRNA technologies. This collective approach supports the rapid commercialization and broader application of microRNA-based advancements.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Ecosystem of the Market
• Supply chain Analysis
• Case study Analysis
• PESTLE Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

MicroRNA Market by Products & Services

• Market Overview
• Services
  • Type
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis
  • Others
  • Specimen
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others
• Products
  • Instruments
  • Technology
  • Real Time PCR
  • Microarray
  • NGS
  • Others
  • Workflow
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis & Others
  • Others
  • Consumables
  • Specimen
  • Workflow
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis & Others
  • Others
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others

MicroRNA Market by Application

• Market Overview
• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others

MicroRNA Market by End-use

• Market Overview
• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Others

MicroRNA Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneCopoeia, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics Ltd. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthego Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asuragen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Molecular Cloud (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ribomed Biotechnologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments